Trpenia

Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis

Jaime Garcia-Chavez & Abraham Majluf-Cruz & Laura Montiel-Cervantes & Miriam García-Ruiz Esparza & Jorge Vela-Ojeda & The Mexican Hematology Study Group

(1) Departamento de Hematología, UMAE "Dr. Antonio Fraga Mouret", Hospital de Especialidades CMN "La Raza", Mexico City, Mexico
(2) Unidad de Investigación Médica en Trombosis, Hemostasia y Aterogénesis, Hospital General Regional Gabriel Mancera, Instituto Mexicano del Seguro Social, Apartado postal 12-1100, Mexico City, México 12 DF, Mexico

Annals of Hematology (2007) 86:871-877

Keywords Chronic ITP. Rituximab . Anti-CD20 . Refractory ITP

Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Francesco Zaja,1 Marta Lisa Battista,1 Maria Teresa Pirrotta,2 Salvatore Palmieri,3 Michela Montagna,4 Nicola Vianelli,5 Luciana Marin,1 Margherita Cavallin,1 Monica Bocchia,2 Marzia Defina,2 Micaela Ippoliti,2 Felicetto Ferrara,3 Francesca Patriarca,1 Maria Antonietta Avanzini,4 Mario Regazzi,4 Michele Baccarani,5 Miriam Isola,6 Franca Soldano,6 and Renato Fanin1

1Clinica Ematologica, DIRM, Azienda Ospedaliera Universitaria, Udine; 2Clinica Ematologica, Policlinico Le Scotte, Siena; 3Divisione di Ematologia, AORN "A. Cardarelli", Napoli; 4Dipartimento di Farmacologia, Fondazione IRCCS Policlinico San Matteo, Pavia; 5Istituto di Ematologia ed Oncologia Medica L. ed A. Seragnoli, Bologna and 6Cattedra di Statistica, DIRM, Università di Udine, Italy

Haematologica 2008; 93:930-933

The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura

Semir Pasa1, Abdullah Altintas1, Timucin Cil2, Ramazan Danis3 and Orhan Ayyildiz1
(1) Department of Hematology, Faculty of Medicine, Dicle University, Diyarbakir, 21280, Turkey
(2) Department of Oncology, Faculty of Medicine, Dicle University, Diyarbakir, 21280, Turkey
(3) Department of Nephrology, Faculty of Medicine, Dicle University, Diyarbakir, 21280, Turkey

J Thromb Thrombolysis (2009) 27:329-333

Keywords Refractory chronic idiopathic thrombocytopenic purpura - Splenectomy - Anti-CD20 monoclonal antibody - Rituximab

pozri abstrakt

Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results

Marta Medeot1, Francesco Zaja1, Nicola Vianelli2, Marta Battista1, Michele Baccarani2, Francesca Patriarca1, Franca Soldano3, Miriam Isola3, Stefano De Luca1, Renato Fanin1

1Clinica Ematologica, DIRM, University of Udine, Udine, Italy; 2Istituto di Ematologia ed Oncologia Medica L. e A. Seragnoli, Bologna, Italy; 3Istituto di Statistica, DIRM, University of Udine, Udine, Italy

European Journal of Haematology 2008 81 (165-169)

Correspondence Francesco Zaja, MD, Clinica Ematologica, University of Udine, P.zza S. Maria della Misericordia, 33100 Udine, Italy. Tel: +39 432 559604; Fax: +39 432 559661; e-mail: zaja.francesco@aoud.sanita.fvg.it

<>

Romiplostim: A novel thrombopoiesis-stimulating agent
Sarah Perreault and Julianna Burzynski

American Journal of Health-System Pharmacy, Vol. 66, Issue 9, 817-824

SARAH PERREAULT, PHARMD., is Clinical Oncology Pharmacist; and. JULIANNA BURZYNSKI, PHARM.D., is Clinical Pharmacy Specialist, Department of Pharmacy, Mayo Clinic, Rochester, MN.

Address correspondence to Dr. Perreault at the Department of Pharmacy, Mayo Clinic, 200 First Street, Rochester, MN 55901 (perreault.sarah@mayo.edu).

Index terms: Costs; Dosage; Drug administration; Mechanism of action; Pharmacokinetics; Purpura; Quality of life; Romiplostim; Thrombopoietic agents; Toxicity

pozri abstrakt

Definition, diagnosis and treatment of immune thrombocytopenic purpura

James N. George
Department of Medicine, College of Medicine, Department of Biostatistics and Epidemiology, College of Public Health,
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
E-mail: james-george@ouhsc.edu. doi:10.3324/haematol.2009.007674

haematologica 2009; 94(6)

Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP)

Kholood Alasfoor1, Mona Alrasheed1, Faisal Alsayegh2 and Shaker A. Mousa3, 4
Contact Information
(1) Department of Medicine, Mubarak Alkabeer Hospital-Ministry of Health-Kuwait, Jabriya, Kuwait
(2) Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait
(3) The Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY, USA
(4) Pharmaceutical Research Institute, 106 New Scotland Avenue, Albany, NY 12208, USA

Annals of Hematology (2009) 88:239-243

A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow upClinically Relevant Abstract

50th ASH Annual Meeting and Exposition
San Francisco
Sunday, December 7, 2008: 2:00 PM
Halls B and C (Moscone Center)

Francesco Zaja1*, Michele Baccarani2, Patrizio Mazza3*, Nicola Vianelli4*, Monica Bocchia5*, Luigi Gugliotta, MD6, Marzia Defina7*, Alessia Tieghi6*, Sergio Amadori8, Selenia Campagna8*, Felicetto Ferrara9, Maria Carla De Simone10*, Alfonso Zaccaria11*, Anna Lia Molinari11*, Emanuele Angelucci12, Emilio Usala12*, Silvia Cantoni13*, Antonella Fornaro14*, Giuseppe Visani15*, Rita Rizzi16*, Valerio De Stefano17*, Francesco Casulli3*, Marta Lisa Battista1*, Miriam Isola18*, Franca Soldano18*, Mario Regazzi19*, Enrica Gamba20* and Renato Fanin1*

1Clinica Ematologica DIRM AOUD, Udine, Italy
2Department of Hematology/Oncology "L. and A. Seragnoli", University of Bologna, Italy
3Ematologia-Taranto, Italy
4Istituto L.A. Seràgnoli-Bologna, Italy
5Clinica Ematologica-Siena, Siena, Italy
6Ematologia-Reggio Emilia, Italy
7Clinica Ematologica-Siena, Italy
8Ematologia Tor Vergata-Roma, Italy
9Department of Hematology, Ospedale Cardarelli, Naples, Italy
10Ematologia Cardarelli-Napoli, Italy
11Ematologia-Ravenna, Italy
12Ematologia-Cagliari, Italy
13Ematologia Niguarda-Milano, Italy
14Ematologia-Pescara, Italy
15Ematologia-Pesaro, Italy
16Clinica Ematologica-Bari, Italy
17Ematologia Cattolica-Roma, Italy
18Istituto Statistica DIRM-Udine, Italy
19Istituto di Farmacologia-Pavia, Italy
20Roche-Monza, Italy

pozri abstrakt prednášky

Léčba imunitní trombocytopenické purpury (ITP)

doc. MUDr. Tomáš Kozák, Ph.D.
Oddělení klinické hematologie, FN Královské Vinohrady a 3. LF Univerzity Karlovy

Možnosti použití monoklonální protilátky anti-CD 20 Rituximab v léčbě chronické formy imunitní trombocytopenie

MUDr. Antonín Hlu?í, Hemato-onkologická klinika FN Olomouc